Survodutide

Concentration: Commonly 5 mg, 10 mg, mg vials (lyophilized powder)

Composition: Synthetic dual agonist peptide (GLP-1R / GCGR)

Formulation: Lyophilized acetate buffered peptide

Half-Life: Extended, designed for once-weekly administration in research

Primary Actions: Dual receptor agonism, weight loss, metabolic studies

Shown to reduce body weight and liver fat in preclinical studies.

Explored for non-alcoholic fatty liver disease (NAFLD) and obesity research.

Demonstrated synergy of GLP-1 and glucagon pathways in metabolism.

Compared with Retatrutide and Semaglutide for efficacy profiles.

Reconstitute with bacteriostatic water (NuroCore standard).

Swirl gently until dissolved completely.

Handle only under sterile laboratory conditions.

Unreconstituted: Store at –20 °C.

Reconstituted: Refrigerate at 2–8 °C.

Appearance: Clear, colorless solution; discard if cloudy or particulate.

Category: Metabolic & Weight Management Research (NuroCore)

Use Case: Research into weight reduction, liver fat, and metabolic pathways

Compliance Note: Classified strictly as a research compound